Jeff Aronin is the chairman and chief executive officer of Paragon Biosciences, an investor and incubator, whose companies are committed to helping people who struggle with diseases for which there are either only a few treatment options available or none exist at all.
In the past 10 years, the Food and Drug Administration approved 13 new medications under Paragon Biosciences executive leadership. The company has accomplished this by following a three-step strategy that includes identifying, building, and developing future products.
Because Jeff Aronin and his colleagues find it important to develop treatments for diseases that have little to no treatment options, the first thing the company needs to do is identify where there is a need for Paragon’s work. The company considers the size of the population affected by the disease as well as the availability, if there are any, of treatments that doctors can currently offer the patients.
Paragon then investigates these patients’ conditions very thoroughly and examines the science behind the disease in order to best address the needs of these people. The company looks at clinical studies and scientific data to drive its drug development strategy (https://www.weizmann-usa.org/get-involved/attend-an-event/2017-midwest-gala-dinner-honoring-jeffrey-aronin).
After successfully identifying what disease a new drug will address, Paragon Biosciences creates dynamic companies that work to create the medicine. It can take years to get life-changing medicine in the hands of patients, but Paragon works to provide long-term resources and all the necessary support to its portfolio companies and ensure the drug development and approval process is as efficient as possible.
Paragon Biosciences likes to support ambitious companies backed by healthcare industry leaders, biotech entrepreneurs, and researchers who dream big and Paragon is willing to commit all of the necessary infrastructures to help them accomplish their goals. Through trial and error and years of hard work, the impossible yields to persistence, passion, and unrelenting creativity. Jeff Aronin and Paragon both have a desire to change the US healthcare industry.
As mentioned earlier in this piece, Paragon Biosciences executive leadership is responsible for the FDA approval of 13 medications in the past decade. That is a better track record than some of the largest pharmaceutical companies can claim.
By applying breakthrough science that is focused on areas of high-unmet medical need, Paragon portfolio companies have rapidly advanced medicines to help those who lack treatment options. In many cases, the drugs that have been created by Paragon’s companies are the first and only approved treatments for the diseases they target.
The companies that Paragon Biosciences has created are instrumental in changing the lives of many patients. For example, Castle Creek is a Paragon portfolio company that focuses on developing innovative therapies for patients with rare, serious, or debilitating dermatologic conditions. The company currently has several products in the late stages of development.
Another company included in Paragon Biosciences’ portfolio called Harmony Biosciences is a biopharmaceutical company focused on identifying, developing, obtaining regulatory approval, and commercializing high-potential, innovative drugs that address unmet needs for patients with sleep and central nervous system disorders.
Jeff Aronin has spent the last 20 years creating companies in the biotech and healthcare industries. Jeff is an expert in the bioscience industry and with his expertise and insight, he has made a big difference in the areas of rare diseases, drug development, and complex science.
Over the years Jeff Aronin has fine-tuned his skills in the areas of brand marketing, finance, and business development. His experience has also made it possible for him to attract top CEO’s and top scientists to the companies included in his portfolio, and help the companies have a successful start. (JeffAronin.com).
Jeff Aronin serves as the non-executive chairman of several Paragon portfolio companies and he has been recognized by several organizations for his work. For example, Jeff received the “Frederic A. Gibbs Discovery Award” and the 2017 Weizmann Leadership Award for his commitment to the bioscience industry.
Jeff was also honored by the Illinois Holocaust Museum & Education Center. This organization presented him with its “2010 Humanitarian Award.” He received the “Rovner Award” from the Epilepsy Foundation of Greater Chicago in 2007. He was also a finalist in the “Entrepreneur of the Year” category that is given by Ernst & Young in 2006.
Most recently, Harmony Biosciences was recognized by Life Sciences Pennsylvania with the “Deal of Year” award for it’s 2017 close to an important sleep disorder medication.
If an organization dedicates itself to improving the lives of anyone who has been diagnosed with a disease, Jeff Aronin will always take interest. That’s why he supports organizations like the Cystic Fibrosis Foundation, Pharmacological Treatment for Epilepsy, JED Foundation for Depression, Juvenile Diabetes Research Foundation (JDRF), and Susan G. Komen Foundation.
Jeff Aronin firmly believes in education, and he demonstrates that by contributing to several education-related charities. The enterprises he supports operate on a local level as well as an international level. Some of these organizations include Big Green, Chicago Parks Foundation, Friends of Israel Defense Forces, Boys and Girls Club of Chicago, US Holocaust Museum, Teaching Tolerance, and the Jewish National Fund.